Fexofenadine in Patients With Active Rheumatoid Arthritis
ConditionRheumatoid Arthritis
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-60
SponsorOctober 6 University
About this trial
Rheumatoid arthritis (RA) is an inflammatory autoimmune polyarthritis affecting ∼1% of the world population, resulting in the loss of joint function and progressive structural damage in affected joints. Fexofenadine has been widely used to treat various allergic diseases, like allergic rhinitis, conjunctivitis and chronic idiopathic urticaria. the molecular mechanisms underlying fexofenadine mediated inhibition of TNF-α signalling
Eligibility criteria
Qualifiers
Moderate to severe RA (disease activity score-28 joints: DAS-28 > 3.2) were recruited.
Age between 18 - 60 years having active disease according to the diagnosis of an experienced rheumatologist, being under treatment with disease-modifying anti-rheumatic drugs (DMARDs), not receiving cytokine inhibitors
Signing informed consent and willingness of the participant to accept randomization to any assigned treatment arm.
Disqualifiers
History of biological DMARDS.
History/presence of acute heart disease, liver and kidney diseases, COPD
Intolerance or allergy to fexofenadine or methotrexate
Alcohol abuse
Trial design
Treatments tested in this trial
- Fexofenadine
- Placebo
Treatment groups
80 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov